SCHEMBL2852078

SCHEMBL2852078

Cc1ccc(-n2cc(C(=O)O)cn2)cc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALKBH2 Q6NS38 2/20 0.72
HPGDS O60760 1/20 0.72
MAPT P10636 4/20 0.61
HPGD P15428 3/20 0.61
ALDH1A1 P00352 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
KDM4E B2RXH2 1/20 0.61
HTT P42858 2/20 0.55
CYP1A2 P05177 1/20 0.53
EGLN1 Q9GZT9 2/20 0.50
HSD11B1 P28845 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182203 0.86 MAP4K4 (0.57) ALKBH2HPGDSMAPTHPGDALDH1A1
SCHEMBL182124 0.86 MAP4K4 (0.57) ALKBH2HPGDSMAPTHPGDALDH1A1
SCHEMBL15331859 0.85 ALKBH2 (0.70) ALKBH2HPGDSMAPTHPGDALDH1A1
SCHEMBL20504240 0.85 MAPT (0.59) ALKBH2HPGDSMAPTHPGDALDH1A1
SCHEMBL70281 0.84 ALKBH2 (1.00) ALKBH2HPGDSMAPTHPGDSMN1; SMN2
SCHEMBL27575419 0.83 ALKBH2 (0.77) ALKBH2HPGDSMAPTHPGDALDH1A1
SCHEMBL9956086 0.83 ALKBH2 (0.62) ALKBH2HPGDSMAPTHPGDHTT
SCHEMBL2850367 0.83 ALKBH2 (0.72) ALKBH2HPGDSMAPTHPGDNPC1
SCHEMBL2856651 0.83 ALKBH2 (0.72) ALKBH2HPGDSMAPTHPGDALDH1A1
SCHEMBL6624522 0.83 HPGDS (0.57) ALKBH2HPGDSMAPTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
CN-114716381-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-07-08 CN disclosed
CN-114634447-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-17 CN disclosed
CN-114605327-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-10 CN disclosed
CN-114591242-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-07 CN disclosed
CN-114573510-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-03 CN disclosed
CN-108473481-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-04-19 CN disclosed
CN-106715395-B 6-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives as TAAR modulators 豪夫迈·罗氏有限公司 2020-05-12 CN disclosed
EP-3174853-B1 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS HOFFMANN LA ROCHE (CH) 2018-12-12 EP disclosed
US-9957261-B2 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives HOFFMAN-LA ROCHE INC. (US) 2018-05-01 US disclosed
EP-3174853-A1 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS F. Hoffmann-La Roche AG (CH) 2017-06-07 EP disclosed
CN-106715395-A 6-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives as TAAR modulators 豪夫迈·罗氏有限公司 2017-05-24 CN disclosed
US-20170137416-A1 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-05-18 US disclosed
WO-2016016162-A1 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2016-02-04 WO disclosed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
WO-2009093012-A1 INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY VERNALIS (R & D) LTD (GB) 2009-07-30 WO disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 ALKBH2 4440/4885HPGDS 1109/4885MAPT 3590/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 ALKBH2 4440/4885HPGDS 1109/4885MAPT 3590/4885
US-20170137416-A1 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES TAAR5, TAAR1, HTR1A ALKBH2 4053/4885HPGDS 2966/4885MAPT 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.